I believe what you're referring to was whether the ANCHOR approval was linked to the outcome of the Reduce-It study. Agreed, they're not at all linked.
This is stating something else:
NCE will happen even if FDA has to change rules, they would have not asked for Reduce-it if generics could be on market at same time
Omthera should be informed that they will run a outcomes study. Cos they don't know about it , according to their webpage. http://www.omthera.com/clinical_trials.html and its the kind of thing they would want to reveal in case they ever run a good ipo.
They got a 6 week Add-on Epanova to Statin Therapy and a Pivotal 12-week Very High Trig planned, and a four-week Pharmacokinetics Epanova Compared to Lovaza study.
Looks like almost a challenge to lovaza. But why ?
News 
Market Data 
Discover 
